Загрузка...
STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer
Trastuzumab‐emtansine (T‐DM1) is an antibody‐drug conjugate that has been approved for the treatment of human epidermal growth factor receptor 2 (HER2)‐positive metastatic breast cancer. Despite the remarkable efficacy of T‐DM1 in many patients, resistance to this therapeutic has emerged as a signif...
Сохранить в:
| Опубликовано в: : | Cancer Sci |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6172075/ https://ncbi.nlm.nih.gov/pubmed/30076657 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13761 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|